Journal
JOURNAL OF IMMUNOLOGY
Volume 192, Issue 12, Pages 5451-5458Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1490019
Keywords
-
Categories
Funding
- Intramural NIH HHS [Z01 BC010984-01] Funding Source: Medline
Ask authors/readers for more resources
The ability of IL-2 to expand T cells with maintenance of functional activity has been translated into the first reproducible effective human cancer immunotherapies. The administration of IL-2 can lead to durable, complete, and apparently curative regressions in patients with metastatic melanoma and renal cancer. The growth of large numbers of tumor-infiltrating lymphocytes with in vitro anti-cancer activity in IL-2 has led to the development of cell transfer therapies that are highly effective in patients with melanoma. The genetic modification of T cells with genes encoding alpha beta TCRs or chimeric Ag receptors and the administration of these cells after expansion in IL-2 have extended effective cell transfer therapy to other cancer types.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available